We've never been closer to accurately assessing whether an individual is more susceptible to developing major depressive ...

Up to 12 months, psychological interventions showed preventive effects for major depressive disorder reducing symptom severity and incidence.

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

—Major depressive disorder and treatment-resistant depression both require high levels of resources—both clinical and economic—across the spectrum of healthcare settings. A new study from ...

Psilocybin is under clinical development by Filament Health and currently in Phase I for Major Depressive Disorder.

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD.